Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
AssigneePfizer Inc.
InventorsAlbert L. Brown, Krishnaswamy Iyengar Dayalu, Thomas James Kaufman, Rex Steven Newsham
Life of this patent
Estimating the term…
Abstract
This invention relates to the field of Pasteurella haemolytica vaccines. More particularly, the invention relates to a bacterin-toxoid vaccine capable of inducing immunity in bovine species in one dose against Pasteurella haemolytica Type A-1 infection comprising Pasteurella haemolytica derived leukotoxoid, capsular antigen, soluble antigens and cells, methods to make the vaccine and methods of vaccinating bovine animals.
Claims29
A bacterin-toxoid vaccine against Pasteurella haemolytica Type A-1 infection, comprising a therapeutically effective amount of Pasteurella haemolytica Type A-1 leukotoxoid, capsular antigen, soluble antigens, and inactivated cells in a density ranging from about 10.sup.3 to about 10.sup.8 cells per ml, which therapeutically effective amount of bacterin-toxoid vaccine provides protection in a bovine species in one dose.
A method of making a bacterin-toxoid vaccine which provides protection in a bovine species in one dose against Pasteurella haemolytica Type A-1 infection, comprising the steps of:
- culturing Pasteurella haemolytica Type A-1 for a time sufficient for said P. haemolytica culture to reach the late logarithmic phase of growth;
- inactivating the P. haemolytica culture;
- and harvesting culture supernatant therefrom comprising leukotoxoid, capsular antigen, soluble antigens, and inactivated P. haemolytica cells at a density ranging from about 10.sup.3 to about 10.sup.8 cells per ml.
A bacterin-toxoid vaccine against Pasteurella haemolytica Type A-1 infection produced by culturing P. haemolytica Type A-1 for a time sufficient for said P. haemolytica culture to reach the late logarithmic phase of growth;
- inactivating the P. haemolytica culture;
- and harvesting the culture supernatant therefrom comprising leukotoxoid, capsular antigen, soluble antigens, and inactivated P. haemolytica cells at a density ranging from about 10.sup.3 to about 10.sup.8 cells per ml.
A method of vaccinating bovine animals against Pasteurella haemolytica consisting of administering to said animals a single dose of a bacterin-toxoid vaccine comprising a therapeutically effective amount of P. haemolytica Type A-1 leukotoxoid, capsular antigen, soluble antigens, and inactivated cells.
A biologically pure culture of Pasteurella haemolytica having all the identifying characteristics of ATCC No. 55318.
A bacterin-toxoid vaccine composition against Pasteurella haemolytica Type A-1 infection, consisting essentially of a therapeutically effective amount of P. haemolytica Type A-1 leukotoxoid, capsular antigen, soluble antigens, inactivated cells in a density ranging from about 10.sup.3 to about 10.sup.8 cells per ml, aluminum hydroxide gel and a mineral oil/lecithin emulsion, said vaccine providing protection in a bovine species in one dose.
A method of making a bacterin-toxoid vaccine which protection in a bovine species in one dose against Pasteurella haemolytica Type A-1 infection, comprising the steps of:
- culturing P. haemolytica Type A-1 for a time sufficient for said culture to reach the late logarithmic phase of growth;
- harvesting culture supernatant therefrom comprising leukotoxin, capsular antigen, soluble antigens, and P. haemolytica cells at a density ranging from about 10.sup.3 to about 10.sup.8 cells per ml;
- and adding an inactivating agent.
A bacterin-toxoid vaccine against Pasteurella haemolytica Type A-1 infection produced by culturing P. haemolytica Type A-1 for a time sufficient for said P. haemolytica culture to reach the late-logarithmic phase of growth;
- harvesting culture supernatant therefrom comprising leukotoxin, capsular antigen, soluble antigens, and P. haemolytica cells at a density ranging from about 10.sup.3 to about 10.sup.8 cells per ml;
- and adding an inactivating agent.
Dependencies are inferred from the claim text.